Alendronate in early postmenopausal women: Effects on bone mass during long-term treatment and after withdrawal

Simple item page
dc.contributor.authorRavn, P
dc.contributor.authorWeiss, SR
dc.contributor.authorRodriguez Portales, JA
dc.contributor.authorMcClung, MR
dc.contributor.authorWasnich, RD
dc.contributor.authorGilchrist, NL
dc.contributor.authorSambrook, P
dc.contributor.authorFogelman, I
dc.contributor.authorKrupa, D
dc.contributor.authorYates, AJ
dc.contributor.authorDaifotis, A
dc.contributor.authorEl Hajj Fuleihan, G
dc.contributor.authorAlendronate Osteoporosis Preventio
dc.date.accessioned2024-01-10T13:10:58Z
dc.date.available2024-01-10T13:10:58Z
dc.date.issued2000
dc.description.abstractWe studied the effect on bone mass of alendronate treatment for 5 yr and its withdrawal. Four hundred and forty-seven postmenopausal women with normal bone mass entered a 3-yr randomized trial followed by a 2-yr open label extension. Three hundred and eleven women completed the first 3 yr, and 263 consented to continue and completed the extension. We are reporting data from groups using the dose of alendronate currently approved for osteoporosis prevention (5 mg) or from the group in which alendronate treatment was withdrawn: 52 women received alendronate (5 mg) for 5 yr (group I), 56 received 3 yr of placebo followed by alendronate (5 mg) for 2 yr (group II), and 52 received alendronate (20 mg) for 2 yr followed by 3 yr off therapy (group III). In group I, alendronate (5 mg) increased bone mineral density (BMD) at the spine and trochanter by 2.5-3.2% (P < 0.001 vs. baseline) and stabilized total body and femoral neck BMD (change vs. baseline, P = NS) over 5 yr. By the end of 5 yr, BMD was comparable at the spine, hip, and total body in groups I and III. The 3-yr decrease in BMD after withdrawal of alendronate (20 mg) in group III was 1.8-5.7% (P < 0.01 vs, baseline) and similar to the 3-yr decrease in BMD in group II during the initial 3 yr. In conclusion, alendronate (5 mg) for 5 yr or alendronate (20 mg) for 2 yr followed by 3 yr off therapy prevented postmenopausal bone lass. After withdrawal of alendronate (20 mg), bone loss resumed at the normal early postmenopausalrate.
dc.fechaingreso.objetodigital2024-05-15
dc.format.extent6 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1210/jc.85.4.1492
dc.identifier.eissn1945-7197
dc.identifier.issn0021-972X
dc.identifier.pubmedidMEDLINE:10770187
dc.identifier.urihttps://doi.org/10.1210/jc.85.4.1492
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/77971
dc.identifier.wosidWOS:000088387200023
dc.information.autorucMedicina;Rodríguez J;S/I;98660
dc.issue.numero4
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final1497
dc.pagina.inicio1492
dc.publisherENDOCRINE SOC
dc.revistaJOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
dc.rightsacceso restringido
dc.subjectORAL ALENDRONATE
dc.subjectCONTROLLED-TRIAL
dc.subjectELDERLY-WOMEN
dc.subjectDOUBLE-BLIND
dc.subjectFOLLOW-UP
dc.subjectOSTEOPOROSIS
dc.subjectPREVENTION
dc.subjectHIP
dc.subjectDISCONTINUATION
dc.subjectBISPHOSPHONATE
dc.subject.ods03 Good Health and Well-being
dc.subject.ods05 Gender Equality
dc.subject.odspa03 Salud y bienestar
dc.subject.odspa05 Igualdad de género
dc.titleAlendronate in early postmenopausal women: Effects on bone mass during long-term treatment and after withdrawal
dc.typeartículo
dc.volumen85
sipa.codpersvinculados98660
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2024-05-15. Alendronate in early postmenopausal women - Effects on bone mass during long-term treatment and after withdrawal.pdf
Size:
2.94 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas